Blood level check could make lung cancer drug work better
NCT ID NCT06195527
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This study looks at 75 adults with non-small cell lung cancer who are receiving pembrolizumab (Keytruda). Researchers want to see if the amount of drug in a patient's blood is linked to how well the cancer shrinks or if side effects occur. By monitoring drug levels over time, they hope to find ways to personalize dosing and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Angers University Hospital
RECRUITINGAngers, 49000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CH Le Mans
NOT_YET_RECRUITINGLe Mans, 53000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.